M&A / Deals Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership pharminent June 4, 2026
Manufacturing Cellares and TScan to assess automated manufacturing of TSC-101 therapy pharminent June 4, 2026
Clinical Data Legend surges on early data for ‘in vivo’ lymphoma cell therapy pharminent June 3, 2026
M&A / Deals Travere beefs up rare kidney disease portfolio with up to $1.1B China deal pharminent June 3, 2026
Regulatory FDA taps prior knowledge to expedite cell and gene therapy development pharminent June 3, 2026
M&A / Deals Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug pharminent June 2, 2026
Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma pharminent June 2, 2026
Clinical Data ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come pharminent June 2, 2026
Regulatory FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients pharminent June 2, 2026
Clinical Data ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off pharminent June 2, 2026
Clinical Data AbiVax falls as safety worries cloud ‘landmark’ immune drug results pharminent June 2, 2026
M&A / Deals Deep Science Ventures and MDC partner to accelerate brain treatments pharminent June 2, 2026
Policy / Pricing The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs pharminent June 2, 2026
Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026
M&A / Deals Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn pharminent June 2, 2026
M&A / Deals CordenPharma inks AmbioPharm buyout to continue peptide production expansion pharminent June 1, 2026
Clinical Data ASCO: Summit reached with China lung data but new climb begins to prove global benefit pharminent June 1, 2026
Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy pharminent June 1, 2026
Clinical Data Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers pharminent May 29, 2026
Regulatory Replimune gives cancer immunotherapy a third try after FDA leadership shakeup pharminent May 29, 2026
M&A / Deals Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent pharminent May 29, 2026
